HomeGMAB • NASDAQ
add
Genmab A/S - ADR
Previous close
$23.49
Day range
$23.40 - $23.56
Year range
$23.24 - $35.88
Market cap
15.50B USD
Avg Volume
515.32K
In the news
Financials
Income Statement
Revenue
Net income
(DKK) | Jun 2024info | Y/Y change |
---|---|---|
Revenue | 5.40B | 29.58% |
Operating expense | 3.40B | 26.72% |
Net income | 1.41B | 5.47% |
Net profit margin | 26.06 | -18.61% |
Earnings per share | 21.70 | 5.29% |
EBITDA | 1.88B | 23.85% |
Effective tax rate | 33.80% | — |
Balance Sheet
Total assets
Total liabilities
(DKK) | Jun 2024info | Y/Y change |
---|---|---|
Cash and short-term investments | 15.73B | -36.77% |
Total assets | 38.62B | 20.77% |
Total liabilities | 7.65B | 137.36% |
Total equity | 30.97B | — |
Shares outstanding | 63.47M | — |
Price to book | 0.05 | — |
Return on assets | 12.06% | — |
Return on capital | 13.86% | — |
Cash Flow
Net change in cash
(DKK) | Jun 2024info | Y/Y change |
---|---|---|
Net income | 1.41B | 5.47% |
Cash from operations | 1.51B | 247.02% |
Cash from investing | -8.77B | -378.04% |
Cash from financing | -3.05B | -43,685.71% |
Net change in cash | -10.34B | -631.19% |
Free cash flow | 1.44B | 797.22% |
About
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, USA, and Genmab K.K. in Tokyo, Japan. Genmab is a dual-listed company with shares traded on both the Copenhagen Stock Exchange in Denmark and the NASDAQ Global Select Market in the US. Wikipedia
Founded
1999
Website
Employees
2,526